DRUG DEAL
swiss drug maker Novartis has swooped on gene therapy firm Avexis for £6.2bn. The move adds a rare- disease treatment to the company’s portfolio that could reap billions in sales.
swiss drug maker Novartis has swooped on gene therapy firm Avexis for £6.2bn. The move adds a rare- disease treatment to the company’s portfolio that could reap billions in sales.